Selleck Chemicals is your Trusted Supplier
for Inhibitors, Antibodies, Proteins, Kits and Reagents

Selleck products have been cited in studies from Nature, Science and Cell.

17 Nobel Prize winners have published 60 papers with Selleck products.
The Nobel Prize

Shimon Sakaguchi, 2025

Nobel Prize in Physiology or Medicine

  • Nature Communications 2025, 16, Article number:1325

David Baker, 2024

Nobel Prize in Chemistry

  • Dev Cell 2023, 58(20):2163-2180.e9.

Katalin Karikó, 2023

Nobel Prize in Physiology or Medicine

  • PLoS One 2015, 10(6):e0131141.

David Julius, 2021

Nobel Prize in Physiology or Medicine

  • Cell 2017, 185-198.e16

Michael Houghton, 2020

Nobel Prize in Physiology or Medicine

  • Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice, 2020

Nobel Prize in Physiology or Medicine

  • Cell, 2018, 172(3):423-438.e25

William G. Kaelin Jr, 2019

Nobel Prize in Physiology or Medicine

  • Cell Metab, 2019, 29(5):1166-1181.e6

Peter J. Ratcliffe, 2019

Nobel Prize in Physiology or Medicine

  • J Clin Invest, 2011, 121(3):1053-63

Gregg L. Semenza, 2019

Nobel Prize in Physiology or Medicine

  • Nat Commun, 2019, 10(1):2130

James P. Allison, 2018

Nobel Prize in Physiology or Medicine

  • Nat Commun, 2017, 8(1):451

Michael Rosbash, 2017

Nobel Prize in Physiology or Medicine

  • Sci Adv. 2020 Aug 12;6(33):eabb8771

Shinya Yamanaka, 2012

Nobel Prize in Physiology or Medicine

  • Sci Transl Med, 2017, 9(391):eaaf3962

Eric Richard Kandel, 2000

Nobel Prize in Physiology or Medicine

  • Cell Rep, 2018, 22(1):59-71

Aziz Sancar, 2015

Nobel Prize in Chemistry

  • Nat Commun, 2016, 7:12180

Brian K. Kobilka, 2012

Nobel Prize in Chemistry

  • Mol Cell, 2019, 75(1):53-65.e7

Robert Lefkowitz, 2012

Nobel Prize in Chemistry

  • Am J Physiol Heart Circ Physiol, 2015, 309(9):H1516-27

Aaron Ciechanover, 2004

Nobel Prize in Chemistry

  • Nat Cell Biol, 2015, 17(7):917-29
Signaling Pathway Inhibitors
PD-1/PD-L1 Inhibitors ROCK Inhibitors Ras Inhibitors TGF-beta/Smad Inhibitors Immunology & Inflammation related Inhibitors CDK Inhibitors DNA/RNA Synthesis Inhibitors Antineoplastic and Immunosuppressive Antibiotics GSK-3 Inhibitors CD markers Inhibitors Ferroptosis Inhibitors & Activators EGFR Inhibitors JAK Inhibitors VEGFR Inhibitors PARP Inhibitors HDAC Inhibitors PI3K Inhibitors Bcl-2 Inhibitors Caspase Inhibitors & Activators Proteasome Inhibitors ATM/ATR Inhibitors Glucagon Receptor Inhibitors HER2 Inhibitors Hydrotropic Agents Inhibitors ADC Inhibitors mTOR Inhibitors Raf Inhibitors Histone Methyltransferase Inhibitors MEK Inhibitors Interleukins Inhibitors Epigenetic Reader Domain Inhibitors Akt Inhibitors Dehydrogenase Inhibitors Wnt/beta-catenin Inhibitors Androgen Receptor Inhibitors STING Inhibitors Estrogen/progestogen Receptor Inhibitors Antibody-Drug Conjugate CSF-1R Inhibitors EZH2 Inhibitors Microtubule Associated Inhibitors STAT Inhibitors Secretase Inhibitors PKA Inhibitors DNA-PK Inhibitors PKC Inhibitors Topoisomerase Inhibitors gp120/CD4 Inhibitors NF-κB Inhibitors AMPK Inhibitors MLL Inhibitors
Featured Products

MRTX1133

MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.

Osunprotafib (ABBV-CLS-484)

Osunprotafib (ABBV-CLS-484) is a potent PTPN1 or PTPN2 inhibitor with a sub-nanomolar activity.

Ralometostat (TNG908)

Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.

IAG933

IAG933 (YAP-TEAD-IN-3) is a small molecule and acts as a YAP/TAZ-TEAD inhibitor. It also inhibits NCI-H2052 and can be used in research of tumor invasion and metastatic spread of solid tumors.

GNE-7883

GNE-7883 is a potent and allosteric small-molecule inhibitor of pan-TEAD, that allosterically blocks the interactions between YAP/TAZ and all human TEAD paralogs through binding to the TEAD lipid pocket. It effectively reduces chromatin accessibility at TEAD motifs, suppresses cell proliferation in a variety of cell line models and achieves strong antitumor efficacy in vivo. Furthermore, it effectively overcomes KRAS G12C inhibitor resistance.

RMC-7977

RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).

Zoldonrasib (RMC-9805)

Zoldonrasib (RMC-9805) is an orally active inhibitor of KRAS G12D. RMC-9805 inhibits RAS signaling, leading to apoptosis in cancer cells with the KRAS G12D mutation.

VT3989

VT3989 (YAP/TAZ inhibitor-3) is a potent and selective oral inhibitor of TEAD auto-palmitoylation, blocking its interaction with yes-associated protein (YAP). It exhibits antitumor activity and shows potential for treating mesothelioma and solid tumors with NF2 mutations.

Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

PD0325901 (Mirdametinib)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

Y-27632 Dihydrochloride

Y-27632 2HCl is a selective ROCK1 and ROCK2 inhibitor with a Ki of 140 nM and 300nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.

SB431542

SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.

Doxorubicin (Adriamycin) Hydrochloride

Doxorubicin Hydrochloride is an antibiotic agent and DNA Topoisomerase II Inhibitor with IC50 of 2.67 μM against human DNA topoisomerase II. This compound reduces basal phosphorylation of AMPK and is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation. This product may precipitate when dissolved in PBS solution. It is recommended to prepare the stock solution in pure water and dilute with either pure water or saline to obtain the working solution. It can be used to induce animal models of kidney disease.

TMZ(Temozolomide)

TMZ(Temozolomide) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

CHIR-99021 (Laduviglusib)

Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.

Bafilomycin A1 (Baf-A1)

Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

Staurosporine (STS)

Staurosporine (STS) is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Thiazovivin (TZV)

Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation.

Forskolin (Colforsin)

Forskolin (Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

MG132

MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.

CX-5461 (Pidnarulex)

Pidnarulex (CX-5461) is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.

Fimepinostat (CUDC-907)

CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. CUDC-907 induces cell cycle arrest and apoptosis in breast cancer cells. Phase 1.

Laduviglusib (CHIR-99021) Hydrochloride

Laduviglusib (CHIR-99021; CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

SBE-β-CD

SBE-β-CD is a novel, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

PEG300

PEG300 (Polyethylene glycol 300) is a water-miscible polyether widely used in biochemistry, structural biology, and medicine in addition to pharmaceutical and chemical industries. It serves as a kind of solubilizer, excipient, lubricant, and chemical reagent. PEG300 helps in the formation of hydrogels in situ upon mixing with silk. These PEG–silk hydrogels are of interest for many biomedical applications, such as anti-fouling and anti-adhesion.

Darovasertib (LXS196)

Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).

Z-VAD-FMK

Z-VAD-FMK (Z-VAD(OMe)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Wnt-C59 (C59)

Wnt-C59 (C59) is a PORCN inhibitor for Wnt3A-mediated activation of a multimerized TCF-binding site driving luciferase with IC50 of 74 pM in HEK293 cells.

BMN-673 (Talazoparib)

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

IWR-1-endo

IWR-1-endo (endo-IWR 1, IWR-1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.

(-)-Blebbistatin

(-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly.

EPZ-6438 (Tazemetostat)

Tazemetostat (EPZ-6438, E7438) is a potent, and selective EZH2 inhibitor with Ki and IC50 of 2.5 nM and 11 nM in cell-free assays, exhibiting a 35-fold selectivity versus EZH1 and >4,500-fold selectivity relative to 14 other HMTs.

RepSox (E-616452)

RepSox (E-616452, SJN 2511, ALK5 Inhibitor II) is a potent and selective inhibitor of the TGFβR-1/ALK5 with IC50 of 23 nM and 4 nM for ATP binding to ALK5 and ALK5 autophosphorylation in cell-free assays, respectively.

Erastin

Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions are unstable and should be fresh-prepared.

AZD9291 (Osimertinib)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

Vactosertib (TEW-7197)

Vactosertib  (TEW-7197, EW-7197) is a highly potent, selective, and orally bioavailable TGF-β receptor ALK4/ALK5 inhibitor with IC50 of 13 nM and 11 nM, respectively. Phase 1.

Telaglenastat (CB-839)

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.

Ceralasertib (AZD6738)

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

Liproxstatin-1

Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM.

GSK1265744 (Cabotegravir)

Cabotegravir (GSK744, GSK1265744, S/GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.

Emricasan (IDN-6556)

Emricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.

Pelabresib (CPI-0610)

Pelabresib (CPI-0610) is a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor with an IC50 of 39 nM for BRD4-BD1 in TR-FRET assay and currently undergoing human clinical trials for hematological malignancies. CPI-0610 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.

Dibutyryl cAMP (db cAMP/Bucladesine) sodium

Bucladesine sodium is a cell-permeable PKA activator by mimicing the action of endogenous cAMP. Dibutyryl-cAMP (Bucladesine) is also a phosphodiesterase (PDE) inhibitor.

ABT-199 (Venetoclax)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Vorapaxar (MK-5348)

Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM.

Nedisertib (M3814)

Nedisertib (M3814, Peposertib, MSC2490484A) is an orally bioavailable, highly potent and selective inhibitor of DNA activated protein kinase (DNA-PK) with IC50 of < 3 nM.

GDC-0077 (Inavolisib)

Inavolisib (GDC-0077, RG6114, RO-7113755) is a potent selective inhibitor of PI3K alpha (PI3Kα) with an IC50 of 0.038 nM. GDC-0077 is >300-fold more selective for PI3K alpha over the other class I PI3K isoforms (beta, delta, and gamma) and >2000-fold more selective over PIK family members. GDC-0077 binds to the ATP binding site of PI3K and inhibits the phosphorylation of PIP2 to PIP3.

BMS-986165 (Deucravacitinib)

Deucravacitinib (BMS-986165) is a highly potent and selective allosteric inhibitor of Tyk2 with a Ki value of 0.02 nM for binding to the Tyk2 pseudokinase domain. It is highly selective against a panel of 265 kinases and pseudokinases.

CD38 inhibitor 1 (compound 78c)

CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.

Zotatifin (eFT226)

Zotatifin (eFT226) is a highly effective and sequence-selective inhibitor of the RNA helicase eIF4A. It promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5'-UTRs, with an IC50 of 2 nM, and disrupts the assembly of the eIF4F initiation complex. By enhancing the interaction between eIF4A and polypurine RNA sequence or structural motifs, zotatifin converts eIF4A into a sequence-specific translation repressor, thereby regulating the translation of certain target genes. It also exhibits anti-tumor activity.